Results 271 to 280 of about 728,843 (299)

Relationships between schizophrenia and the alarmins interleukin-33 (IL-33), soluble receptor of interleukin-33 (sST2) and the ratio IL-33/sST2. A systematic review

Journal of Psychiatric Research
Schizophrenia is a multi-aetiologic disease. Inflammation have recently been involved in its pathophysiology. Recent research suggests that inflammation may be a key factor in its pathophysiology. Alarmins, interleukin-33 (IL-33), its soluble receptor sST2 and the ratio IL-33/sST2, have been investigated as neuroinflammation biomarkers.
Jose Juan, Tascon-Cervera, Maria Lourdes, Fernandez-Lopez, Armando Luis, Morera-Fumero   +2 more
openaire   +2 more sources

Targeting interleukin-33 in rheumatoid arthritis

Rheumatology International, 2011
Chao, Rong, Wei, Hu, Fan-Rong, Wu, Fei-Hu, Chen   +3 more
openaire   +2 more sources

Interleukin-33

2014
Sangmin Jeong, Soohyun Kim
openaire   +1 more source

Interlinking interleukin-33 (IL-33), neuroinflammation and neuropathic pain

2022
Camila Rodrigues Ferraz, Fernanda Soares Rasquel-Oliveira, Sergio Marques Borghi, Anelise Franciosi, Thacyana Teixeira Carvalho, Telma Saraiva-Santos, Nayara Anitelli Artero, Rubia Casagrande, Waldiceu A. Verri   +8 more
openaire   +1 more source

Interleukin-33 (IL-33; NF-HEV)

Science-Business eXchange, 2008
openaire   +1 more source

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Lancet, The, 2008
Andrea Rubbert-Roth, César R Ramos-Remus, Rieke E Alten   +2 more
exaly  

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2015
Iain B Mcinnes, Philip J Mease, Bruce W Kirkham   +2 more
exaly  

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Nature Reviews Drug Discovery, 2012
Charles A Dinarello, Anna Simon, Jos W M Van Der Meer   +2 more
exaly  

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Lancet, The, 2013
Antoinette Moran, Linda A Dimeglio, Stephen E Gitelman   +2 more
exaly  

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Lancet, The, 2017
B G Feagan, Julian Panes, Arthur Kaser
exaly